The Texas Supreme Court (SCOTX) issued a major ruling on May 1, 2026, affirming the state’s authority to classify Delta-8 THC and other manufactured analogues as Schedule I controlled substances.
The decision reverses a four-year-old injunction that had protected the multi-billion dollar hemp-derived THC market, though a separate trial court ruling has provided a new, temporary shield for retailers.
The SCOTX ruling in Texas DSHS v. Sky Marketing Corp. concludes that the Texas Department of State Health Services (DSHS) has the broad, discretionary authority to ban synthetic THC isomers that do not naturally occur in the hemp plant at potent levels.
However, the legal landscape remains in flux; the Texas Hemp Business Council (THBC) says they recently secured a new temporary injunction in a separate lawsuit, blocking 2026 DSHS regulations that sought to ban THCA flower and significantly increase licensing fees. This means that while the state has won the high-level legal argument over its authority, the specific enforcement of a ban remains stalled in lower courts.
Writing for the unanimous Court, Justice Evan Young stated that the lower courts “exceeded their authority” by blocking the state’s 2021 classification of Delta-8. The Court found that the 2019 Texas Farm Bill decontrolled only the “exceedingly trace amounts” of Delta-8 that naturally occur in the hemp plant, not high-potency versions manufactured through chemical conversion in a lab.
Justice Young argued that if the legislature intended such a major change to social policy as legalizing powerful drugs, it would have done so “unmistakably”. The opinion further noted that administrative agencies must have the discretion to respond rapidly to “emerging threats to public safety”.
The ruling prompted immediate reactions from state and federal officials. Senator Charles Perry (R-Lubbock), author of the state’s hemp legislation in 2025, stated that the law is now “abundantly clear” and argued that these “dangerous THC analogue products” should be removed from shelves immediately.
His comments coincided with a May 4, 2026, Federal Register notice from the DEA formally designating Hexahydrocannabinol (HHC) as a Schedule I substance, assigning it a unique drug code to facilitate federal tracking. Additionally, federal officials from the Trump Administration’s Office of National Drug Control Policy (ONDCP) reaffirmed that Delta-8 and Delta-10 are considered controlled substances under federal law.
Despite this pressure, the Texas Hemp Business Council maintains that its members are protected by the new trial court order. The current injunction blocks DSHS from implementing a “total THC” testing standard that would have effectively banned THCA flower, as well as a proposed increase in licensing fees from $150 to $5,000.
THBC argues that these agency rules attempt to “replace” legislative policy rather than implement it. This ongoing litigation ensures that hemp-derived products will likely remain available through the summer as the secondary lawsuit proceeds.
“Until there is a clear withdrawal of the commissioner’s discretion, no court can properly deem the commissioner’s listing decisions to have been made ultra vires,” the Supreme Court concluded.